Sarepta Therapeutics Inc (SRPT)
117.09
+0.23
(+0.20%)
USD |
NASDAQ |
Apr 23, 16:00
117.09
0.00 (0.00%)
After-Hours: 20:00
Sarepta Therapeutics Research and Development Expense (Quarterly): 195.52M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 195.52M |
| September 30, 2023 | 194.30M |
| June 30, 2023 | 241.89M |
| March 31, 2023 | 245.68M |
| December 31, 2022 | 213.80M |
| September 30, 2022 | 216.71M |
| June 30, 2022 | 252.33M |
| March 31, 2022 | 194.25M |
| December 31, 2021 | 197.30M |
| September 30, 2021 | 139.12M |
| June 30, 2021 | 239.62M |
| March 31, 2021 | 195.15M |
| December 31, 2020 | 207.24M |
| September 30, 2020 | 190.44M |
| June 30, 2020 | 188.52M |
| March 31, 2020 | 136.14M |
| December 31, 2019 | 223.14M |
| September 30, 2019 | 133.95M |
| June 30, 2019 | 113.27M |
| March 31, 2019 | 90.55M |
| December 31, 2018 | 146.21M |
| September 30, 2018 | 86.58M |
| June 30, 2018 | 122.85M |
| March 31, 2018 | 46.20M |
| December 31, 2017 | 44.44M |
| Date | Value |
|---|---|
| September 30, 2017 | 34.24M |
| June 30, 2017 | 58.91M |
| March 31, 2017 | 29.12M |
| December 31, 2016 | 70.75M |
| September 30, 2016 | 34.35M |
| June 30, 2016 | 44.35M |
| March 31, 2016 | 38.83M |
| December 31, 2015 | 41.38M |
| September 30, 2015 | 36.67M |
| June 30, 2015 | 29.18M |
| March 31, 2015 | 39.16M |
| December 31, 2014 | 30.83M |
| September 30, 2014 | 21.85M |
| June 30, 2014 | 20.64M |
| March 31, 2014 | 20.91M |
| December 31, 2013 | 25.08M |
| September 30, 2013 | 21.09M |
| June 30, 2013 | 12.98M |
| March 31, 2013 | 13.76M |
| December 31, 2012 | 12.83M |
| September 30, 2012 | 10.91M |
| June 30, 2012 | 13.85M |
| March 31, 2012 | 14.80M |
| December 31, 2011 | 18.70M |
| September 30, 2011 | 15.61M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
113.27M
Minimum
Jun 2019
252.33M
Maximum
Jun 2022
195.70M
Average
195.52M
Median
Dec 2023
Research and Development Expense (Quarterly) Benchmarks
| PTC Therapeutics Inc | 121.35M |
| Vertex Pharmaceuticals Inc | 824.60M |
| Regenxbio Inc | 55.68M |
| CytomX Therapeutics Inc | 19.39M |
| Apellis Pharmaceuticals Inc | 69.28M |